LUBAC: A Protein Involved in Linear Ubiquitin Chain Assembly and Cellular Processes

Target Name: Linear Ubiquitin Chain Assembly Complex (LUBAC)

NCBI ID: P28492

Linear Ubiquitin Chain Assembly Complex (LUBAC)

Other Name(s): Linear Ubiquitin Chain Assembly Complex | LUBAC

LUBAC: A Protein Involved in Linear Ubiquitin Chain Assembly and Cellular Processes

The Linear Ubiquitin Chain Assembly Complex (LUBAC) is a protein that plays a crucial role in the assembly of linear ubiquitin chains, which are a type of protein-protein interaction that is important for many cellular processes. LUBAC is composed of a chain of amino acids acids that forms a circular structure and contains a domain that is responsible for bringing together other proteins to form the linear ubiquitin chain.

The LUBAC protein is found in many different cell types and is involved in a wide range of cellular processes, including the regulation of protein stability and the degradation of damaged proteins. LUBAC is also a potential drug target and has been shown to play a role in several diseases, including cancer and neurodegenerative diseases.

One of the unique features of LUBAC is its ability to form a stable linear ubiquitin chain. This is important for the regulation of protein stability and for the function of many different proteins. LUBAC helps to ensure that proteins such as ubiquitinase are able to bind to on modified proteins to maintain the stability of these proteins.

LUBAC is also involved in the degradation of damaged proteins. Within cells, proteins are usually in a relatively stable state, but when proteins are damaged, they usually cannot be degraded in time, which may lead to protein accumulation and the occurrence of disease. . LUBAC plays an important role in degrading damaged proteins by forming linear ubiquitin chains, allowing proteins such as ubiquitinase to bind to modified proteins, thus accelerating the degradation process.

In addition, LUBAC is involved in many important biological processes, including cell division, apoptosis, and cell signaling. In these processes, LUBAC plays a key role in helping cells carry out normal physiological activities.

In recent years, researchers have conducted in-depth studies on the function of LUBAC and found that LUBAC may be a potential drug target. Especially in neurodegenerative diseases, the function of LUBACs has received more attention.

For example, activation of LUBAC leads to phosphorylation of Tau protein in neurons, leading to neuronal loss. In addition, activation of LUBAC can also lead to Cu/Zn ion imbalance in neurons, thus affecting the normal function of neurons.

In addition, activation of LUBAC also affects neuronal apoptosis. In neurons, activation of LUBAC leads to the activation of apoptotic signaling pathways in neurons, leading to neuronal apoptosis.

Other relationships exist between LUBAC activation and neurodegenerative diseases. For example, there is a link between LUBAC activation and the incidence of Parkinson's disease. Furthermore, activation of LUBAC has been associated with the incidence of Alzheimer's disease.

Therefore, LUBAC is a potential drug target for the treatment of many neurodegenerative diseases.

Protein Name: Linear Ubiquitin Chain Assembly Complex (LUBAC)

The "Linear Ubiquitin Chain Assembly Complex (LUBAC) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Linear Ubiquitin Chain Assembly Complex (LUBAC) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets